These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9850267)

  • 1. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
    Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
    Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
    Chen TC
    J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
    Osborne SA; Montgomery DM; Morris D; McKay IC
    Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
    Bowman RJ; Cope J; Nischal KK
    Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
    Yuen NS; Cheung P; Hui SP
    Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic reactions to brimonidine in patients treated for glaucoma.
    Blondeau P; Rousseau JA
    Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
    Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
    Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation.
    Thompson CD; Macdonald TL; Garst ME; Wiese A; Munk SA
    Exp Eye Res; 1997 May; 64(5):767-73. PubMed ID: 9245907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with apraclonidine 0.5%.
    Gross RL; Pinyero A; Orengo-Nania S
    J Glaucoma; 1997 Oct; 6(5):298-302. PubMed ID: 9327348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
    Barnes SD; Campagna JA; Dirks MS; Doe EA
    Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions.
    Butler P; Mannschreck M; Lin S; Hwang I; Alvarado J
    Arch Ophthalmol; 1995 Mar; 113(3):293-6. PubMed ID: 7887842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.